News

Cellebrite Prepares to Share Third-Quarter Insights Soon

Cellebrite Prepares to Share Third-Quarter Insights Soon

Cellebrite to Share Third-Quarter 2025 Financial Results

TYSONS CORNER, Va. and PETAH TIKVA, Israel – In an exciting announcement, Cellebrite (NASDAQ: CLBT), a leader in digital investigative solutions for both public and private sectors, confirmed its plans to report its financial results for the third quarter of 2025 after the U.S. market closes on November 12, 2025.

Live Discussion to Unfold on Financial Performance

On the same day as the report, Cellebrite will host a live conference call and webcast to discuss these financial results in detail. This is an excellent opportunity for stakeholders to gain insights into the company's performance and outlook for the remainder of the year.

Conference Call Details

The important details for the conference call on November 12 include:

  • Date: November 12, 2025
  • Time: 5:00 p.m. ET
  • Call-In Number: 203-518-9814 / 800-274-8461
  • Conference ID: CLBTQ325
  • Live Webcast: Join here

Cellebrite's Commitment to Transparency

In conjunction with the conference call and webcast, historical financial tables and supplementary data will be made available online on the investor relations section of Cellebrite's website. Investors and analysts looking for comprehensive information can access it there, ensuring transparency and thoroughness in reporting the company’s financial standing.

Understanding Cellebrite's Mission

Cellebrite's mission revolves around enabling its global customer base to protect and enhance lives. By enhancing digital investigations and intelligence gathering, Cellebrite plays a crucial role in accelerating justice within communities around the world. Their AI-powered Digital Investigation Platform is a key pillar of this mission, making it possible for customers to access, collect, analyze, and share digital evidence within a legal framework while respecting data privacy.

Wide Range of Services and Solutions

Thousands of organizations, including public safety groups, intelligence agencies, and businesses, rely on Cellebrite’s digital forensic and investigative solutions. These services, available via cloud, on-premises, or hybrid deployments, enable faster case closures and help safeguard communities effectively.

Stay Connected with Cellebrite

For more information about Cellebrite and its offerings, visit the company's website. Engaging users are invited to follow them on various social media platforms at @Cellebrite to stay updated on their latest developments and innovations.

Investor Relations

For inquiries related to investor relations, Andrew Kramer serves as the Vice President and can be reached at investors@cellebrite.com or via phone at +1 973.206.7760.

Media Contact Information

Victor Cooper, the Senior Director of Corporate Communications and Content Operations, is the media contact. He can be reached at Victor.cooper@cellebrite.com or at +1 404.804.5910.

Frequently Asked Questions

What is the date of Cellebrite's financial report?

The financial report for Q3 2025 will be announced on November 12, 2025.

How can I access the live conference call?

The conference call can be accessed through the provided call-in numbers or by attending the live webcast online.

What is Cellebrite's mission?

Cellebrite aims to enhance digital investigations and intelligence gathering to help protect and save lives while ensuring data privacy.

What services does Cellebrite provide?

Cellebrite offers digital forensic and investigative solutions tailored for public safety organizations and businesses, available via various deployment options.

Who should I contact for investor relations inquiries?

For investor relations questions, reach out to Andrew Kramer, Vice President of Investor Relations, via email or phone.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BioVid Debuts AI to Mimic Physician Decision-Making

Updated Category News Views 47

Revolutionizing Understanding: BioVid Mimetics™ Now here's something that's shaking the research tree: BioVid's launching Mimetics™, and it's a big deal. They've come up with AI that can mirror how physicians think and decide. This ain't your run-of-the-mill tech stuff—it's groundbreaking in understanding physician decision-making. The Core: How Do Doctors Really...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 111

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
AZ Health Workers Step Up for Community Wellness

Updated Category News Views 4

Health Screenings: A Step Before the Hospital Sometimes it's the basics, like a plain old health screening, that can shift the tides from crisis to care. That's exactly where AZ Blue Health Choice and Zeihan ProHealth come into the picture, aiming to pin those health concerns before they spiral out of control. For your average Arizonan who finds healthcare as elusive as a...

Continue Reading
Enigmata Innovates AI Security with Finovifi Tie-Up

Updated Category News Views 94

Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...

Continue Reading
Podcast Giants Converge in Tennessee for POD U Summit

Updated Category News Views 57

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Continue Reading
Home Insurance Gaps: Risky Assumptions Uncovered

Updated Category News Views 53

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Continue Reading
Americas Cardroom Smashes Prize Pools; Bahamas Up Next

Updated Category News Views 49

Ah, poker. Where dreams are won with a flick of the wrist and a well-placed bluff. This week, it was all eyes on Americas Cardroom’s Dual Venom PKOs, and let me tell you, they didn't just meet expectations—they chewed them up and spat them out like yesterday's jam. Two Titans Crowned in Poker Showdown The action wrapped up with a jaw-dropping $6,862,500 prize pool....

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 37

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
Savvy Moves: Avoiding Pitfalls When Buying Used Vans

Updated Category News Views 14

When you're eyeing a used work van, don't just kick the tires and jot down the mileage—there's a whole backyard BBQ checklist you need to chew through. Tony Collichio, the work van guru from Spencerport, lays it down for us, highlighting key questions to ask before pulling out the checkbook. And let me tell you, these aren’t your everyday 'how does it drive?' queries....

Continue Reading
Abbott's Oncodetect Test: Game-Changer for Cancer Recurrence

Updated Category News Views 4

Pioneering Progress in Colorectal Cancer Detection There's a new player in the world of cancer diagnostics, and it's setting a fresh standard. Abbott's Oncodetect test, featured at the ESMO Congress, has shown a profound leap in sensitivity—30 percent over the older whole-exome sequencing approach. For those doing the math on the stock charts, Abbott (NYSE: ABT) is...

Continue Reading

Top 5 Most Recently Viewed Articles

Clare Locke Advocates for Megan Thee Stallion in Defamation Case

Updated Category News Views 111

Clare Locke LLP Champions Megan Thee Stallion's Defamation Case Clare Locke LLP, a respected name in defamation law, has taken a bold step to support Megan Thee Stallion's pursuit of justice against Milagro Cooper. The firm has filed a motion for leave to present an amicus brief that specifically endorses Megan's effort to have a jury's defamation ruling reinstated. This...

Continue Reading
Bankers Signal Looming Economic Challenges Amid Uncertainty

Updated Category News Views 167

Bankers Signal Looming Economic Challenges Amid Uncertainty Interest rate fluctuations, credit quality, and tariffs are significant concerns for financial institutions. A recent survey highlights the anxiety among bankers regarding the economic climate and impending recession. Survey Highlights Economic Fears According to a survey from fintech IntraFi, which gathered...

Continue Reading
Dave Portnoy Questions Elon Musk Amid Tesla's Plummeting Stock

Updated Category News Views 162

Tesla's Stock Dilemma: Portnoy's Concerns Tesla’s stock, designated as TSLA, has recently experienced a significant decline, stirring up discussions among investors and enthusiasts alike. Dave Portnoy, the founder of Barstool Sports, has voiced his frustration regarding this situation, bringing forth some pointed questions about Elon Musk’s priorities. In a recent...

Continue Reading
Akropolis Group's Credit Rating Affirmed Amid Strategic Changes

Updated Category News Views 88

Akropolis Group’s Robust Credit Rating Amid Strategic Reassessments Renowned international credit rating agency S&P Global Ratings recently evaluated the financial outlook for Akropolis Group, a prominent player in the real estate development and management sector. This assessment took into account significant structural governance changes within the Vilniaus Prekyba...

Continue Reading
Arcutis Takes a Significant Step with ZORYVE Cream for Kids

Updated Category News Views 156

Arcutis Advances ZORYVE® Cream for Pediatric Use Arcutis Biotherapeutics, Inc. is making headlines with its recent submission of a supplemental New Drug Application (sNDA) aimed at expanding the use of ZORYVE (roflumilast) cream 0.3% to treat plaque psoriasis in children as young as 2 years old. If approved, ZORYVE would be the first topical PDE4 inhibitor specifically...

Continue Reading